318 related articles for article (PubMed ID: 29021448)
1. Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis.
Namba M; Masuda T; Nakamura T; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Intern Med; 2017 Dec; 56(24):3327-3331. PubMed ID: 29021448
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis.
Ohara T; Oto T; Miyoshi K; Tao H; Yamane M; Toyooka S; Okazaki M; Date H; Sano Y
Ann Thorac Surg; 2008 Dec; 86(6):e7-8. PubMed ID: 19021963
[TBL] [Abstract][Full Text] [Related]
3. Chyloperitoneum, chylothorax and lower extremity lymphedema in woman with sporadic lymphangioleiomyomatosis successfully treated with sirolimus: a case report.
Chachaj A; Drozdz K; Chabowski M; Dziegiel P; Grzegorek I; Wojnar A; Jazwiec P; Szuba A
Lymphology; 2012 Jun; 45(2):53-7. PubMed ID: 23057149
[TBL] [Abstract][Full Text] [Related]
4. Peritoneovenous shunt for chylous ascites after lung transplantation for lymphangioleiomyomatosis.
Kanou T; Nakagiri T; Minami M; Inoue M; Shintani Y; Okumura M
Transplant Proc; 2012 Jun; 44(5):1390-3. PubMed ID: 22664021
[TBL] [Abstract][Full Text] [Related]
5. Octreotide Use in Neonates: A Case Series.
Zaki SA; Krishnamurthy MB; Malhotra A
Drugs R D; 2018 Sep; 18(3):191-198. PubMed ID: 29948779
[TBL] [Abstract][Full Text] [Related]
6. Durability of Sirolimus for Lymphangioleiomyomatosis.
Martirossian A; Shah S; Carrete L; Valle J; Valentine V
Am J Med Sci; 2017 Dec; 354(6):603-607. PubMed ID: 29208258
[TBL] [Abstract][Full Text] [Related]
7. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.
Ando K; Kurihara M; Kataoka H; Ueyama M; Togo S; Sato T; Doi T; Iwakami S; Takahashi K; Seyama K; Mikami M
Respir Investig; 2013 Sep; 51(3):175-83. PubMed ID: 23978644
[TBL] [Abstract][Full Text] [Related]
9. Lymphangioleiomyomatosis manifesting as refractory chylothorax and chyloperitoneum.
Chen YS; Memon P
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31300601
[TBL] [Abstract][Full Text] [Related]
10. Midodrine, an Oral Alpha-1 Adrenoreceptor Agonist, Successfully Treated Refractory Congenital Chylous Pleural Effusion and Ascites in a Neonate.
Tamaoka S; Osada A; Kin T; Arimitsu T; Hida M
Chest; 2021 Apr; 159(4):e189-e191. PubMed ID: 34022016
[TBL] [Abstract][Full Text] [Related]
11. Peritoneovenous shunt after failure of octreotide treatment for chylous ascites in lymphangioleiomyomatosis.
Lefrou L; d'Alteroche L; Harchaoui Y; Franco D; Metman EH
Dig Dis Sci; 2007 Nov; 52(11):3188-90. PubMed ID: 17638079
[No Abstract] [Full Text] [Related]
12. Use of Propranolol in the Treatment of Chylous Effusions in Infants.
Mitchell K; Weiner A; Ramsay P; Sahni M
Pediatrics; 2021 Jul; 148(1):. PubMed ID: 34187907
[TBL] [Abstract][Full Text] [Related]
13. [A case of lymphangioleiomyomatosis found due to chylous ascites, pleural effusion and pelvic lymphadenopathy].
Yano T; Hasizume I; Kasamatsu N; Kato T; Shibata M; Ashinuma N; Kobayashi K; Yasuda T; Nakamura A
Nihon Kokyuki Gakkai Zasshi; 2007 May; 45(5):399-403. PubMed ID: 17554983
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of sirolimus therapy for chylous effusions in lymphangioleiomyomatosis.
Barrera P; Simons SO; Luijk B; Wessels MJ; Heijdra YF
Ann Am Thorac Soc; 2013 Aug; 10(4):408-9. PubMed ID: 23952870
[No Abstract] [Full Text] [Related]
15. Use of octreotide in the treatment of chylothorax and chyloperitoneum.
Pessotti CF; Jatene IB; Buononato PE; Elias PF; Pinto AC; Kok MF
Arq Bras Cardiol; 2011 Aug; 97(2):e33-6. PubMed ID: 22002034
[TBL] [Abstract][Full Text] [Related]
16. Octreotide in the outpatient therapy of cirrhotic chylous ascites: a case report.
Berzigotti A; Magalotti D; Cocci C; Angeloni L; Pironi L; Zoli M
Dig Liver Dis; 2006 Feb; 38(2):138-42. PubMed ID: 16389001
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.
Harari S; Elia D; Torre O; Bulgheroni E; Provasi E; Moss J
Chest; 2016 Aug; 150(2):e29-32. PubMed ID: 27502989
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation.
Sugimoto R; Nakao A; Yamane M; Toyooka S; Okazaki M; Aoe M; Seyama K; Date H; Oto T; Sano Y
J Heart Lung Transplant; 2008 Aug; 27(8):921-4. PubMed ID: 18656809
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary lymphangiomyomatosis (LAM) developing chylothorax.
Morimoto N; Hirasaki S; Kamei T; Horiike A; Miyatake H; Ogita Y; Nakano H
Intern Med; 2000 Sep; 39(9):738-41. PubMed ID: 10969906
[TBL] [Abstract][Full Text] [Related]
20. Concurrent occurrence of chylothorax, chylous ascites, and protein-losing enteropathy in systemic lupus erythematosus.
Lee CK; Han JM; Lee KN; Lee EY; Shin JH; Cho YS; Koh Y; Yoo B; Moon HB
J Rheumatol; 2002 Jun; 29(6):1330-3. PubMed ID: 12064855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
